

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-39. (canceled).

40. (currently amended) A method of administering an oligonucleotide to a mammal, the method comprising administering to the alimentary canal of the mammal a composition comprising an oligonucleotide, said oligonucleotide comprises SEQ ID NO: 1 and has ~~having~~ at least one internucleotide linkage that is a methylene(methylimino) backbone modification, whereby ~~a percent bioavailability of at least about 11.5% of~~ bioavailability is ~~that~~ achieved via intravenous administration ~~is achieved~~.

41. (previously presented) The method of claim 40, wherein the oligonucleotide has at least one phosphodiester linkage.

42. (previously presented) The method of claim 40, wherein the oligonucleotide has alternating methylene(methylimino) and phosphodiester internucleoside linkages.

43-51. (canceled)